Clarity Pharmaceuticals Ltd (CLRPF)

Market Cap	753.33M -18.3%
Revenue (ttm)	7.06M -1.8%
Net Income	-64.26M
EPS	-0.19
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	2.000
Previous Close	2.020
Day's Range	2.000 - 2.020
52-Week Range	1.232 - 3.600
Beta	1.18
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLRPF

Financial Performance

In fiscal year 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 11, 2026

Data Sources Report a data error